118 228

Cited 37 times in

Serum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma

DC FieldValueLanguage
dc.contributor.author이승우-
dc.contributor.author정문재-
dc.contributor.author정재복-
dc.contributor.author박승우-
dc.contributor.author박정엽-
dc.contributor.author송시영-
dc.date.accessioned2014-12-18T08:38:49Z-
dc.date.available2014-12-18T08:38:49Z-
dc.date.issued2013-
dc.identifier.issn0513-5796-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/86694-
dc.description.abstractPURPOSE: To investigate the use of pretreatment carbohydrate antigen (CA) 19-9 and carcinoembryonic antigen (CEA) as prognostic factors to determine survival in pancreatic adenocarcinoma. MATERIALS AND METHODS: A retrospective review of the medical records of patients who were diagnosed with pancreatic adenocarcinoma and received surgery, chemoradiotherapy or chemotherapy was performed. Factors, including CA 19-9 and CEA, associated with the survival of pancreatic cancer patients were analyzed. RESULTS: Patients with the median age of 65 years were included (n=187). Elevated serum CA 19-9 levels and CEA levels were observed in 75.4% and 39% of patients at diagnosis, respectively. CEA was correlated with tumor stages (p=0.005), but CA 19-9 was not. CA 19-9 and CEA were elevated in 69.0% and 33.3% of patients with resectable pancreatic cancer, and elevated in 72.9% and 47.2% of patients with advanced pancreatic cancer, respectively. The median overall survival of the normal serum CEA group was longer than that of the elevated serum CEA group (16.3 months vs. 10.2 months, p=0.004). However, the median overall survival of the normal serum CA 19-9 group was not different from that of the elevated serum CA 19-9 group (12.4 months vs. 13.5 months, p=0.969). The independent factors associated with overall survival were advanced pancreatic cancer [harzard ratio (HR) 4.33, p=0.001] and elevated serum CEA level (HR 1.52, p=0.032). CONCLUSION: Patients with elevated serum CEA level at diagnosis demonstrated poor overall survival. Pretreatment CEA level may predict the prognosis of patients with pancreatic adenocarcinoma.-
dc.description.statementOfResponsibilityopen-
dc.relation.isPartOfYONSEI MEDICAL JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdenocarcinoma/blood-
dc.subject.MESHAdenocarcinoma/diagnosis*-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAntigens, Tumor-Associated, Carbohydrate/blood*-
dc.subject.MESHCarcinoembryonic Antigen/blood*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPancreatic Neoplasms/blood-
dc.subject.MESHPancreatic Neoplasms/diagnosis*-
dc.subject.MESHPrognosis-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHSurvival Analysis-
dc.titleSerum CA 19-9 and CEA Levels as a Prognostic Factor in Pancreatic Adenocarcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorKyong Joo Lee-
dc.contributor.googleauthorSeung Woo Yi-
dc.contributor.googleauthorMoon Jae Chung-
dc.contributor.googleauthorSeung Woo Park-
dc.contributor.googleauthorSi Young Song-
dc.contributor.googleauthorJae Bock Chung-
dc.contributor.googleauthorJeong Youp Park-
dc.identifier.doi10.3349/ymj.2013.54.3.643-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA02920-
dc.contributor.localIdA03602-
dc.contributor.localIdA03706-
dc.contributor.localIdA01551-
dc.contributor.localIdA01647-
dc.contributor.localIdA02035-
dc.relation.journalcodeJ02813-
dc.identifier.eissn1976-2437-
dc.identifier.pmid23549809-
dc.subject.keywordCA 19-9-
dc.subject.keywordcarcinoembryonic antigen-
dc.subject.keywordpancreas adenocarcinoma-
dc.subject.keywordprognosis-
dc.contributor.alternativeNameYi, Seung Woo-
dc.contributor.alternativeNameChung, Moon Jae-
dc.contributor.alternativeNameChung, Jae Bock-
dc.contributor.alternativeNamePark, Seung Woo-
dc.contributor.alternativeNamePark, Jeong Youp-
dc.contributor.alternativeNameSong, Si Young-
dc.contributor.affiliatedAuthorYi, Seung Woo-
dc.contributor.affiliatedAuthorChung, Moon Jae-
dc.contributor.affiliatedAuthorChung, Jae Bock-
dc.contributor.affiliatedAuthorPark, Seung Woo-
dc.contributor.affiliatedAuthorPark, Jeong Youp-
dc.contributor.affiliatedAuthorSong, Si Young-
dc.rights.accessRightsfree-
dc.citation.volume54-
dc.citation.number3-
dc.citation.startPage643-
dc.citation.endPage649-
dc.identifier.bibliographicCitationYONSEI MEDICAL JOURNAL, Vol.54(3) : 643-649, 2013-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.